Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3561180 | 0.98 | DPP4 (0.42) | DPP4HTR2CAVPR1AOPRL1KMT2A | |
| Butane SCHEMBL8575686 | 0.93 | HTR2C (0.39) | DPP4HTR2CAVPR1AOPRL1CTSC | |
| SCHEMBL737193 | 0.89 | DPP4 (0.42) | DPP4HTR2CAVPR1ANR3C2 | |
| SCHEMBL4977596 | 0.84 | KDM1A (0.40) | DPP4HTR2COPRL1KMT2AKDM1A | |
| SCHEMBL1588901 | 0.80 | AVPR1A (0.38) | AVPR1ACTSCKDM1ASLC5A1SLC5A2 | |
| SCHEMBL18373201 | 0.80 | HTR2C (0.40) | HTR2CCTSCKDM1A | |
| SCHEMBL4045773 | 0.80 | HTR2C (0.44) | HTR2CAVPR1AKDM1A | |
| SCHEMBL3745692 | 0.80 | HTR2C (0.38) | HTR2CSLC5A1SLC5A2 | |
| SCHEMBL31415656 | 0.77 | SIGMAR1 (0.53) | AVPR1A | |
| SCHEMBL8871048 | 0.77 | SIGMAR1 (0.53) | AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107916-B1 | SPIRO-OXAZOLONES | HOFFMANN LA ROCHE (CH) | 2019-03-20 | — | — | EP | disclosed |
| US-9828385-B2 | Spiro-oxazolones | HOFFMANN-LA ROCHE INC. (US) | 2017-11-28 | — | — | US | disclosed |
| EP-3107916-A1 | SPIRO-OXAZOLONES | F. Hoffmann-La Roche AG (CH) | 2016-12-28 | — | — | EP | disclosed |
| US-20160355522-A1 | SPIRO-OXAZOLONES | HOFFMANN-LA ROCHE INC. (US) | 2016-12-08 | — | — | US | disclosed |
| WO-2015124541-A1 | SPIRO-OXAZOLONES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-27 | — | — | WO | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9040525-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-8765752-B2 | 3-hydroxyisothiazole 1-oxide derivatives | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2703393-A1 | CYCLIC AMIDE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20060281746-A1 | Cyclopropyl derivatives as nk3 receptor antagonists | H. LUNDBECK A/S (DK) | 2006-12-14 | — | — | US | disclosed |
| WO-2006092731-A1 | 1, 2, 4-TRIAZOLE DERIVATIVES AND THEIR USE AS OXYTOCIN ANTAGONISTS | PFIZER LIMTED (GB) | 2006-09-08 | — | — | WO | disclosed |
| US-20060173027-A1 | Spirocvclic piperidines as mch1 antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2006-08-03 | — | — | US | disclosed |
| EP-1656349-A1 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | H. Lundbeck A/S (DK) | 2006-05-17 | — | — | EP | disclosed |
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | ITO FUMITAKA (JP) | 2005-07-14 | — | — | US | disclosed |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | H. LUNDBECK A/S (DK) | 2005-03-31 | — | — | US | disclosed |
| WO-2005016913-A1 | TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS | PFIZER JAPAN, INC. (JP) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016884-A1 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | H. LUNDBECK A/S (DK) | 2005-02-24 | — | — | WO | disclosed |
| EP-1458714-A1 | 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES | H. Lundbeck A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051869-A1 | 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES | H. LUNDBECK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153998-A1 | Tetrahydroisoquinoline or isochroman compounds | OPRL1, NR1H3, HRH3 | DPP4 3894/4885HTR2C 358/4885AVPR1A 295/4885 |
| US-20160355522-A1 | SPIRO-OXAZOLONES | AVPR1A, AVPR1B, AVPR2 | DPP4 1864/4885HTR2C 63/4885AVPR1A 1/4885 |
| US-20050070713-A1 | 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives | KCNJ2, KCNK2, KCNJ11 | DPP4 716/4885HTR2C 504/4885AVPR1A 400/4885 |
| US-20060173027-A1 | Spirocvclic piperidines as mch1 antagonists and uses thereof | MCHR1, MCHR2, CRHR1 | DPP4 1659/4885HTR2C 50/4885AVPR1A 34/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | DPP4 2063/4885HTR2C 929/4885AVPR1A 301/4885 |
| US-20060281746-A1 | Cyclopropyl derivatives as nk3 receptor antagonists | TACR2, SLC6A3, TACR1 | DPP4 2508/4885HTR2C 708/4885AVPR1A 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.